A. Karim Kader, MD, PhD, FRCSC, presented “The Role of Genetic Testing in Prostate Cancer” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Kader, A. Karim. “The Role of Genetic Testing in Prostate Cancer” January 23rd, 2020. Accessed Oct 2020. https://grandroundsinurology.com/the-role-of-genetic-testing-in-prostate-cancer/
The Role of Genetic Testing in Prostate Cancer – Summary:
A. Karim Kader, MD, PhD, FRCSC, Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, argues that genomic risk stratification plays an important role in our understanding of prostate cancer. He highlights the differences between germline and somatic genomic classifiers and the impact they can have on prostate cancer risk and outcome. Dr. Kader discusses the advantages and disadvantages of a wide range of genetic tests. Additionally, he discusses the differences between high penetrance and low penetrance genetic change and the implications they can have on screening, detection, and treatment decisions.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Kader delivered this educational activity during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.